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 What Comes First in Brand Decline –
Lower Loyalty or Lower Patronage?
By Samantha Buxton, Philip Stern and Jaap Wieringa
Background
Previous research has focused on two main scenarios that exist within 
the new and existing brand markets. These are; near instant loyalty and 
trial preceding loyalty (Schweidel and Fader 2009). Very little research 
had focused on brand decline. 
Pharmaceuticals
Pharmaceutical companies need to maintain sales levels just before and 
following generic launches. Klemperer (1987), Shugan (1980) and 
Janakiraman, Dutta Sismeiro and Stern (2008) found that physicians 
exhibit persistence in their prescribing behaviour and posit a number of 
reasons for this.
Ehrenberg, Uncles and Goodhardt (2004) found that high loyalty tends to 
be driven generally by light buyers. This may be due to the fact they are 
100% loyal as they made few purchases. 
Stern and Hammond (2004) found that the results found by 
Ehrenberg et al (2004) only holds true if  the light and heavy buyers 
are compared from the same time period. 
Decline and the lifecycle
Cox (1967)  developed a way to measure the product lifecycle of a 
prescription drug, but  focused on the overall lifecycle rather than a 
specific phase.
Kvesic (2008) suggests a number of ways to manage the decline of 
a brand. These include: attempting to maximize loyalty, investing in 
generics and developing over-the-counter sales.
Sahoo (2006) suggests that promotion in the late stages of a drug’s 
lifecycle may maximize brand loyalty thus maintaining visibility when 
other branded drugs and generic alternatives enter the market. 
Current Research
The objective of this research is to examine the patterns for a declining 
brand, which (as the reverse of a new launch) should show one of three 
patterns 
1) Coincident reduction of patronage and loyalty
2) Initial reduction in loyalty followed by reduced patronage
3) Initial reduction in patronage followed by reduced loyalty 
There has been no prior research which examines which of these 
three scenarios best describe how brands decline, This research 
will examine the empirical patterns of a number of drugs over an 
extended time-scale.
This exploratory analysis focuses on Omeprazole, a gastrointestinal drug 
produced by AstraZeneca. 
Figure 1. Shows the sales for Omeprazole between 1995-2005. The data 
shows the 12 month moving average  sales measured as the number of 
new or switch prescriptions written per 100 GP’s.  This measure allows for 
the exclusion of repeat prescriptions for ongoing chronic conditions. This 
means only active prescribing decisions are measured.  
Omeprazole sales started to decline in early 1995  and continued to 
decline until the start of 2004 when sales grew again rapidly. This is 
an especially interesting example as the drug lost patent protection 
in 2002.
Figures 2 and 3 show the percentage of prescribers and the average 
frequency of prescribing during the same time period.
Figure 3 shows that the average frequency does not (like penetration) 
initially fall with sales. The frequency level is maintained for about a year 
before starting to fall. This pattern is repeated in 1998 when penetration 
falls but frequency stays constant. Interestingly, the second growth period 
beginning in 2004 appears to be coincidental penetration and loyalty 
growth (near instant loyalty). 
Conclusion
This exploratory analysis finds support for the ‘reducing patronage model 
of declining brands. Further research is underway to examine the extent 
to which this pattern generalises across other drugs in both the same and 
other categories.
Implications of current research for managers
Coincident decline in patronage and loyalty would imply that existing 
marketing programmes be maintained or increased.
Initially declining loyalty implies a focus on maintaining share of 
category requirements.
Initially declining patronage indicates a need for customer acquisition.
Early results indicate that brand decline starts with reduced patronage 
not with lower loyalty and this would suggest maintained or even 
increased detailing activities.
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Figure 1: Sales of 
Omeprazole over ten 
years
Figure 2: Penetration of 
Omeprazole
The penetration can be 
seen to track the changes 
in sales very closely (the 
correlation is >0.96).
Figure 3: shows that 
average frequency does 
not initially fall with 
sales (unlike penetration 
shown in Figure 2) 
